Role of gemcitabine in ovarian cancer treatment

A. Lorusso, A. Di Stefano, F. Fanfani, Giovanni Scambia

Research output: Contribution to journalArticlepeer-review


Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown promising activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogues, Gemcitabine has been combined with Carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of Gemcitabine and other agents, including paclitaxel, are also feasible and have been actively studied in order to establish the role of Gemcitabine in the management of treated and untreated ovarian cancer patients.

Original languageEnglish
JournalAnnals of Oncology
Issue numberSUPPL. 5
Publication statusPublished - May 2006


  • Gemcitabine
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Role of gemcitabine in ovarian cancer treatment'. Together they form a unique fingerprint.

Cite this